Universe Pharmaceuticals Inc. (UPC) 10-Year Financial Performance & Capital Metrics

UPC • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

AboutUniverse Pharmaceuticals INC, a pharmaceutical company, engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China. It offers products for the treatment of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party producers, including biomedical drugs, medical instruments, traditional Chinese medicine pieces products, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains. The company was incorporated in 2019 and is based in Ji'An, China. Universe Pharmaceuticals INC is a subsidiary of Sununion Holding Group Limited.Show more

Revenue $23M -28.7%
EBITDA -$8M -149.6%
Net Income -$9M -41.6%
EPS (Diluted) -1436.12 -38.0%
Gross Margin 26.37% -17.4%
EBITDA Margin -32.72% -250.3%
Operating Margin -34.83% -219.1%
Net Margin -37.9% -98.7%
ROE -20.53% -43.2%
ROIC -18.88% -201.1%
Debt/Equity 0.18 +26.7%
Interest Coverage -28.83 -28.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Negative free cash flow
✗Sales declining 7.1% over 5 years
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-7.07%

3Y-21.71%

TTM-44.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-230.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM-310.26%

ROCE

10Y Avg34.87%

5Y Avg11.19%

3Y Avg-13.31%

Latest-18.4%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.51B	9.77	30.53	-0.61%	11.72%	16.31%	4.71%	0.62
UPCUniverse Pharmaceuticals Inc.	2.59M	4.59	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	711.94K	0.17	-0.07	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	20.24M	0.54	-0.46	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.09B	15.17	-12.14	-6.06%	-1.21%	-1.17%	11.72%	0.84

Profit & Loss

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	28.51M	33.23M	30.7M	47.98M	40.14M	32.31M	23.02M
Revenue Growth %	-	0.17%	-0.08%	0.56%	-0.16%	-0.2%	-0.29%
Cost of Goods Sold+	15.11M	19.82M	16.61M	22.66M	18.25M	21.99M	16.95M
COGS % of Revenue	0.53%	0.6%	0.54%	0.47%	0.45%	0.68%	0.74%
Gross Profit+	13.41M	13.41M	14.09M	25.33M	21.89M	10.32M	6.07M
Gross Margin %	0.47%	0.4%	0.46%	0.53%	0.55%	0.32%	0.26%
Gross Profit Growth %	-	-0%	0.05%	0.8%	-0.14%	-0.53%	-0.41%
Operating Expenses+	3.65M	3.36M	3.74M	11.74M	28.91M	13.84M	14.09M
OpEx % of Revenue	0.13%	0.1%	0.12%	0.24%	0.72%	0.43%	0.61%
Selling, General & Admin	2.39M	2.29M	2.8M	6.27M	21.3M	9M	10.44M
SG&A % of Revenue	0.08%	0.07%	0.09%	0.13%	0.53%	0.28%	0.45%
Research & Development	789.38K	618.44K	583.13K	5.47M	7.62M	4.86M	3.03M
R&D % of Revenue	0.03%	0.02%	0.02%	0.11%	0.19%	0.15%	0.13%
Other Operating Expenses	474.63K	445.77K	365.77K	0	-7.53K	-17.53K	616.27K
Operating Income+	9.66M	9.75M	10.25M	13.59M	-7.02M	-3.53M	-8.02M
Operating Margin %	0.34%	0.29%	0.33%	0.28%	-0.17%	-0.11%	-0.35%
Operating Income Growth %	-	0.01%	0.05%	0.33%	-1.52%	0.5%	-1.27%
EBITDA+	10.11M	10.17M	10.66M	14.04M	-6.49M	-3.02M	-7.53M
EBITDA Margin %	0.35%	0.31%	0.35%	0.29%	-0.16%	-0.09%	-0.33%
EBITDA Growth %	-	0.01%	0.05%	0.32%	-1.46%	0.53%	-1.5%
D&A (Non-Cash Add-back)	452.73K	418.43K	410.08K	446.88K	533.95K	508.79K	485.73K
EBIT	9.68M	9.78M	10.22M	13.78M	-6.93M	-3.69M	-7.84M
Net Interest Income+	-164.92K	-129.27K	-123.76K	-101.6K	-162.4K	-156.79K	-278.17K
Interest Income	0	0	0	0	0	0	0
Interest Expense	164.92K	129.27K	123.76K	101.6K	162.4K	156.79K	278.17K
Other Income/Expense	-138.28K	-99.77K	-151.29K	57.51K	-545.35K	-413.77K	-100.75K
Pretax Income+	9.52M	9.65M	10.1M	13.65M	-7.98M	-3.94M	-8.12M
Pretax Margin %	0.33%	0.29%	0.33%	0.28%	-0.2%	-0.12%	-0.35%
Income Tax+	1.92M	2.1M	2.54M	2.36M	752.42K	2.25M	606.7K
Effective Tax Rate %	0.8%	0.78%	0.75%	0.83%	1.09%	1.56%	1.07%
Net Income+	7.6M	7.55M	7.56M	11.32M	-8.74M	-6.16M	-8.73M
Net Margin %	0.27%	0.23%	0.25%	0.24%	-0.22%	-0.19%	-0.38%
Net Income Growth %	-	-0.01%	0%	0.5%	-1.77%	0.29%	-0.42%
Net Income (Continuing)	7.6M	7.55M	7.56M	11.29M	-8.74M	-6.19M	-8.73M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	1303.36	1294.54	1295.70	2147.18	-1475.02	-1040.53	-1436.12
EPS Growth %	-	-0.01%	0%	0.66%	-1.69%	0.29%	-0.38%
EPS (Basic)	1303.36	1294.54	1295.70	2147.18	-1475.02	-1040.53	-1436.12
Diluted Shares Outstanding	5.83K	5.83K	5.83K	5.27K	5.92K	5.92K	6.08K
Basic Shares Outstanding	5.83K	5.83K	5.83K	5.27K	5.92K	5.92K	6.08K
Dividend Payout Ratio	0.4%	2.12%	-	-	-	-	-

Balance Sheet

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	21.96M	12.23M	22.84M	50.48M	41.51M	36.81M	51.64M
Cash & Short-Term Investments	6.19M	3.18M	10.06M	21.8M	18.86M	18.5M	29.5M
Cash Only	6.19M	3.18M	10.06M	8.08M	5.71M	5.29M	29.5M
Short-Term Investments	0	0	0	13.73M	13.15M	13.22M	0
Accounts Receivable	7.64M	6.42M	10.87M	15.81M	15.18M	10.73M	17.88M
Days Sales Outstanding	97.76	70.53	129.24	120.27	138.06	121.21	283.4
Inventory	8.12M	2.62M	1.91M	2.46M	2.21M	3.34M	1.74M
Days Inventory Outstanding	196.22	48.16	41.89	39.67	44.13	55.48	37.4
Other Current Assets	0	0	443.71K	174.05K	1.72M	626.24K	852.42K
Total Non-Current Assets+	6.12M	5.61M	5.52M	19.66M	18.03M	16.48M	16.32M
Property, Plant & Equipment	5.08M	4.57M	4.43M	15.39M	13.58M	14.99M	15.34M
Fixed Asset Turnover	5.62x	7.28x	6.93x	3.12x	2.96x	2.16x	1.50x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	183.58K	171.61K	174.78K	178.48K	157.45K	148.58K	262.88K
Long-Term Investments	728K	700.5K	735K	744.92K	702.89K	685.31K	712.49K
Other Non-Current Assets	0	0	0	2.48M	2.25M	0	0
Total Assets+	28.08M	17.84M	28.8M	70.14M	59.54M	53.29M	67.95M
Asset Turnover	1.02x	1.86x	1.07x	0.68x	0.67x	0.61x	0.34x
Asset Growth %	-	-0.36%	0.61%	1.44%	-0.15%	-0.11%	0.28%
Total Current Liabilities+	18.4M	5.45M	8M	11.21M	13.1M	13.75M	20.31M
Accounts Payable	2.94M	1.94M	2.69M	5.31M	3.08M	4.59M	4.91M
Days Payables Outstanding	71	35.67	59.14	85.56	61.5	76.1	105.82
Short-Term Debt	2.62M	2.52M	2.65M	4.33M	3.94M	5.48M	5.86M
Deferred Revenue (Current)	893.51K	0	0	0	0	0	0
Other Current Liabilities	-893.51K	0	956.49K	0	3.38M	0	0
Current Ratio	1.19x	2.24x	2.85x	4.50x	3.17x	2.68x	2.54x
Quick Ratio	0.75x	1.76x	2.62x	4.28x	3.00x	2.43x	2.46x
Cash Conversion Cycle	222.98	83.02	111.99	74.39	120.68	100.6	214.98
Total Non-Current Liabilities+	0	0	0	0	7.01M	0	2.14M
Long-Term Debt	0	0	0	0	0	0	2.14M
Capital Lease Obligations	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	18.4M	5.45M	8M	11.21M	13.1M	13.75M	22.45M
Total Debt+	2.62M	2.52M	2.65M	4.33M	3.94M	5.48M	7.99M
Net Debt	-3.57M	-655.52K	-7.41M	-3.74M	-1.78M	197.21K	-21.5M
Debt / Equity	0.27x	0.20x	0.13x	0.07x	0.08x	0.14x	0.18x
Debt / EBITDA	0.26x	0.25x	0.25x	0.31x	-	-	-
Net Debt / EBITDA	-0.35x	-0.06x	-0.70x	-0.27x	-	-	-
Interest Coverage	58.55x	75.45x	82.84x	133.76x	-43.22x	-22.49x	-28.83x
Total Equity+	9.68M	12.38M	20.8M	58.93M	46.44M	39.53M	45.5M
Equity Growth %	-	0.28%	0.68%	1.83%	-0.21%	-0.15%	0.15%
Book Value per Share	1659.79	2123.10	3566.42	11178.75	7841.01	6674.44	7487.73
Total Shareholders' Equity	9.68M	12.38M	20.8M	58.93M	46.44M	39.53M	45.5M
Common Stock	50K	50K	50K	67.97K	67.97K	67.97K	482.4K
Retained Earnings	2.83M	6.18M	13.74M	25.06M	16.32M	10.16M	-10.17M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	3.12M	2.47M	3.33M	4.53M	772.83K	26.27K	1.33M
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	4.46M	13.2M	6.12M	-2.06M	-1.31M	1.12M	-9.51M
Operating CF Margin %	0.16%	0.4%	0.2%	-0.04%	-0.03%	0.03%	-0.41%
Operating CF Growth %	-	1.96%	-0.54%	-1.34%	0.36%	1.85%	-9.49%
Net Income	7.6M	7.55M	7.56M	11.32M	-7.91M	-6.58M	-8.73M
Depreciation & Amortization	452.73K	418.43K	410.08K	446.88K	533.95K	508.79K	485.73K
Stock-Based Compensation	0	0	0	0	0	0	0
Deferred Taxes	17.54K	-39.63K	-9.89K	-668.34K	-542.38K	1.57M	606.7K
Other Non-Cash Items	-85.19K	112.79K	22.71K	-468.17K	5.97K	-45.74K	186.19K
Working Capital Changes	-3.53M	5.16M	-1.87M	-12.69M	6.6M	5.67M	-2.06M
Change in Receivables	-2.82M	665.49K	-4.11M	-3.87M	-1.55M	4.72M	-1.71M
Change in Inventory	-327.26K	5.59M	888.61K	-451.63K	16.59K	-1.18M	1.64M
Change in Payables	265.17K	-924.44K	639.43K	2.46M	-1.9M	1.64M	143.75K
Cash from Investing+	-145.09K	-86.03K	-51.8K	-27.06M	-3.91M	-44.17K	-361.29K
Capital Expenditures	-145.09K	-86.32K	-51.8K	-13.53M	-93.7K	-44.17K	-245.8K
CapEx % of Revenue	0.01%	0%	0%	0.28%	0%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	-26.62M	523	0	-115.49K
Cash from Financing+	-4.91M	-16M	470.14K	26.58M	3.32M	-1.39M	33.95M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-3.06M	-16M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	0	-441.06K	-2.79M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	4.31M	13.12M	6.06M	-15.59M	-1.41M	1.08M	-9.87M
FCF Margin %	0.15%	0.39%	0.2%	-0.32%	-0.04%	0.03%	-0.43%
FCF Growth %	-	2.04%	-0.54%	-3.57%	0.91%	1.77%	-10.17%
FCF per Share	738.99	2248.83	1039.49	-2956.58	-237.39	181.65	-1624.12
FCF Conversion (FCF/Net Income)	0.59x	1.75x	0.81x	-0.18x	0.15x	-0.18x	1.09x
Interest Paid	183.07K	135.72K	157.53K	149.3K	199.85K	190.18K	304.52K
Taxes Paid	1.7M	2.26M	2.17M	3.27M	2.75M	863.8K	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	78.53%	68.45%	45.55%	28.39%	-16.58%	-14.34%	-20.53%
Return on Invested Capital (ROIC)	118.49%	82%	61.22%	29.72%	-10.54%	-6.27%	-18.88%
Gross Margin	47.03%	40.35%	45.9%	52.78%	54.53%	31.93%	26.37%
Net Margin	26.66%	22.73%	24.62%	23.59%	-21.76%	-19.08%	-37.9%
Debt / Equity	0.27x	0.20x	0.13x	0.07x	0.08x	0.14x	0.18x
Interest Coverage	58.55x	75.45x	82.84x	133.76x	-43.22x	-22.49x	-28.83x
FCF Conversion	0.59x	1.75x	0.81x	-0.18x	0.15x	-0.18x	1.09x
Revenue Growth	-	16.54%	-7.6%	56.27%	-16.34%	-19.52%	-28.74%

Frequently Asked Questions

Growth & Financials

Universe Pharmaceuticals Inc. (UPC) reported $46.0M in revenue for fiscal year 2024. This represents a 61% increase from $28.5M in 2018.

Universe Pharmaceuticals Inc. (UPC) saw revenue decline by 28.7% over the past year.

Universe Pharmaceuticals Inc. (UPC) reported a net loss of $17.5M for fiscal year 2024.

Dividend & Returns

Universe Pharmaceuticals Inc. (UPC) has a return on equity (ROE) of -20.5%. Negative ROE indicates the company is unprofitable.

Universe Pharmaceuticals Inc. (UPC) had negative free cash flow of $11.1M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Universe Pharmaceuticals Inc. (UPC) 10-Year Financial Performance & Capital Metrics

UPC • • Industrial / General

HealthcareSpecialty & Generic PharmaConsumer HealthcareOTC Medications

Revenue $23M -28.7%
EBITDA -$8M -149.6%
Net Income -$9M -41.6%
EPS (Diluted) -1436.12 -38.0%
Gross Margin 26.37% -17.4%
EBITDA Margin -32.72% -250.3%
Operating Margin -34.83% -219.1%
Net Margin -37.9% -98.7%
ROE -20.53% -43.2%
ROIC -18.88% -201.1%
Debt/Equity 0.18 +26.7%
Interest Coverage -28.83 -28.2%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Trading at only 0.0x book value

✗Weaknesses

✗Weak Piotroski F-Score: 0/9
✗Negative free cash flow
✗Sales declining 7.1% over 5 years
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-7.07%

3Y-21.71%

TTM-44.08%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-230.69%

EPS CAGR

10Y-

5Y-

3Y-

TTM-310.26%

ROCE

10Y Avg34.87%

5Y Avg11.19%

3Y Avg-13.31%

Latest-18.4%

Peer Comparison

OTC Medications

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
HLNHaleon plc	43.51B	9.77	30.53	-0.61%	11.72%	16.31%	4.71%	0.62
UPCUniverse Pharmaceuticals Inc.	2.59M	4.59	-0.00	-28.74%	-37.94%	-31.64%		0.18
PRPHProPhase Labs, Inc.	711.94K	0.17	-0.07	-84.75%	-38.72%	-6.08%		3.34
COSMCosmos Health Inc.	20.24M	0.54	-0.46	1.97%	-31.01%	-80.15%		0.48
PRGOPerrigo Company plc	2.09B	15.17	-12.14	-6.06%	-1.21%	-1.17%	11.72%	0.84

Profit & Loss

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Sales/Revenue+	28.51M	33.23M	30.7M	47.98M	40.14M	32.31M	23.02M
Revenue Growth %	-	0.17%	-0.08%	0.56%	-0.16%	-0.2%	-0.29%
Cost of Goods Sold+	15.11M	19.82M	16.61M	22.66M	18.25M	21.99M	16.95M
COGS % of Revenue	0.53%	0.6%	0.54%	0.47%	0.45%	0.68%	0.74%
Gross Profit+	13.41M	13.41M	14.09M	25.33M	21.89M	10.32M	6.07M
Gross Margin %	0.47%	0.4%	0.46%	0.53%	0.55%	0.32%	0.26%
Gross Profit Growth %	-	-0%	0.05%	0.8%	-0.14%	-0.53%	-0.41%
Operating Expenses+	3.65M	3.36M	3.74M	11.74M	28.91M	13.84M	14.09M
OpEx % of Revenue	0.13%	0.1%	0.12%	0.24%	0.72%	0.43%	0.61%
Selling, General & Admin	2.39M	2.29M	2.8M	6.27M	21.3M	9M	10.44M
SG&A % of Revenue	0.08%	0.07%	0.09%	0.13%	0.53%	0.28%	0.45%
Research & Development	789.38K	618.44K	583.13K	5.47M	7.62M	4.86M	3.03M
R&D % of Revenue	0.03%	0.02%	0.02%	0.11%	0.19%	0.15%	0.13%
Other Operating Expenses	474.63K	445.77K	365.77K	0	-7.53K	-17.53K	616.27K
Operating Income+	9.66M	9.75M	10.25M	13.59M	-7.02M	-3.53M	-8.02M
Operating Margin %	0.34%	0.29%	0.33%	0.28%	-0.17%	-0.11%	-0.35%
Operating Income Growth %	-	0.01%	0.05%	0.33%	-1.52%	0.5%	-1.27%
EBITDA+	10.11M	10.17M	10.66M	14.04M	-6.49M	-3.02M	-7.53M
EBITDA Margin %	0.35%	0.31%	0.35%	0.29%	-0.16%	-0.09%	-0.33%
EBITDA Growth %	-	0.01%	0.05%	0.32%	-1.46%	0.53%	-1.5%
D&A (Non-Cash Add-back)	452.73K	418.43K	410.08K	446.88K	533.95K	508.79K	485.73K
EBIT	9.68M	9.78M	10.22M	13.78M	-6.93M	-3.69M	-7.84M
Net Interest Income+	-164.92K	-129.27K	-123.76K	-101.6K	-162.4K	-156.79K	-278.17K
Interest Income	0	0	0	0	0	0	0
Interest Expense	164.92K	129.27K	123.76K	101.6K	162.4K	156.79K	278.17K
Other Income/Expense	-138.28K	-99.77K	-151.29K	57.51K	-545.35K	-413.77K	-100.75K
Pretax Income+	9.52M	9.65M	10.1M	13.65M	-7.98M	-3.94M	-8.12M
Pretax Margin %	0.33%	0.29%	0.33%	0.28%	-0.2%	-0.12%	-0.35%
Income Tax+	1.92M	2.1M	2.54M	2.36M	752.42K	2.25M	606.7K
Effective Tax Rate %	0.8%	0.78%	0.75%	0.83%	1.09%	1.56%	1.07%
Net Income+	7.6M	7.55M	7.56M	11.32M	-8.74M	-6.16M	-8.73M
Net Margin %	0.27%	0.23%	0.25%	0.24%	-0.22%	-0.19%	-0.38%
Net Income Growth %	-	-0.01%	0%	0.5%	-1.77%	0.29%	-0.42%
Net Income (Continuing)	7.6M	7.55M	7.56M	11.29M	-8.74M	-6.19M	-8.73M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0
EPS (Diluted)+	1303.36	1294.54	1295.70	2147.18	-1475.02	-1040.53	-1436.12
EPS Growth %	-	-0.01%	0%	0.66%	-1.69%	0.29%	-0.38%
EPS (Basic)	1303.36	1294.54	1295.70	2147.18	-1475.02	-1040.53	-1436.12
Diluted Shares Outstanding	5.83K	5.83K	5.83K	5.27K	5.92K	5.92K	6.08K
Basic Shares Outstanding	5.83K	5.83K	5.83K	5.27K	5.92K	5.92K	6.08K
Dividend Payout Ratio	0.4%	2.12%	-	-	-	-	-

Balance Sheet

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Total Current Assets+	21.96M	12.23M	22.84M	50.48M	41.51M	36.81M	51.64M
Cash & Short-Term Investments	6.19M	3.18M	10.06M	21.8M	18.86M	18.5M	29.5M
Cash Only	6.19M	3.18M	10.06M	8.08M	5.71M	5.29M	29.5M
Short-Term Investments	0	0	0	13.73M	13.15M	13.22M	0
Accounts Receivable	7.64M	6.42M	10.87M	15.81M	15.18M	10.73M	17.88M
Days Sales Outstanding	97.76	70.53	129.24	120.27	138.06	121.21	283.4
Inventory	8.12M	2.62M	1.91M	2.46M	2.21M	3.34M	1.74M
Days Inventory Outstanding	196.22	48.16	41.89	39.67	44.13	55.48	37.4
Other Current Assets	0	0	443.71K	174.05K	1.72M	626.24K	852.42K
Total Non-Current Assets+	6.12M	5.61M	5.52M	19.66M	18.03M	16.48M	16.32M
Property, Plant & Equipment	5.08M	4.57M	4.43M	15.39M	13.58M	14.99M	15.34M
Fixed Asset Turnover	5.62x	7.28x	6.93x	3.12x	2.96x	2.16x	1.50x
Goodwill	0	0	0	0	0	0	0
Intangible Assets	183.58K	171.61K	174.78K	178.48K	157.45K	148.58K	262.88K
Long-Term Investments	728K	700.5K	735K	744.92K	702.89K	685.31K	712.49K
Other Non-Current Assets	0	0	0	2.48M	2.25M	0	0
Total Assets+	28.08M	17.84M	28.8M	70.14M	59.54M	53.29M	67.95M
Asset Turnover	1.02x	1.86x	1.07x	0.68x	0.67x	0.61x	0.34x
Asset Growth %	-	-0.36%	0.61%	1.44%	-0.15%	-0.11%	0.28%
Total Current Liabilities+	18.4M	5.45M	8M	11.21M	13.1M	13.75M	20.31M
Accounts Payable	2.94M	1.94M	2.69M	5.31M	3.08M	4.59M	4.91M
Days Payables Outstanding	71	35.67	59.14	85.56	61.5	76.1	105.82
Short-Term Debt	2.62M	2.52M	2.65M	4.33M	3.94M	5.48M	5.86M
Deferred Revenue (Current)	893.51K	0	0	0	0	0	0
Other Current Liabilities	-893.51K	0	956.49K	0	3.38M	0	0
Current Ratio	1.19x	2.24x	2.85x	4.50x	3.17x	2.68x	2.54x
Quick Ratio	0.75x	1.76x	2.62x	4.28x	3.00x	2.43x	2.46x
Cash Conversion Cycle	222.98	83.02	111.99	74.39	120.68	100.6	214.98
Total Non-Current Liabilities+	0	0	0	0	7.01M	0	2.14M
Long-Term Debt	0	0	0	0	0	0	2.14M
Capital Lease Obligations	0	0	0	0	0	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	0
Total Liabilities	18.4M	5.45M	8M	11.21M	13.1M	13.75M	22.45M
Total Debt+	2.62M	2.52M	2.65M	4.33M	3.94M	5.48M	7.99M
Net Debt	-3.57M	-655.52K	-7.41M	-3.74M	-1.78M	197.21K	-21.5M
Debt / Equity	0.27x	0.20x	0.13x	0.07x	0.08x	0.14x	0.18x
Debt / EBITDA	0.26x	0.25x	0.25x	0.31x	-	-	-
Net Debt / EBITDA	-0.35x	-0.06x	-0.70x	-0.27x	-	-	-
Interest Coverage	58.55x	75.45x	82.84x	133.76x	-43.22x	-22.49x	-28.83x
Total Equity+	9.68M	12.38M	20.8M	58.93M	46.44M	39.53M	45.5M
Equity Growth %	-	0.28%	0.68%	1.83%	-0.21%	-0.15%	0.15%
Book Value per Share	1659.79	2123.10	3566.42	11178.75	7841.01	6674.44	7487.73
Total Shareholders' Equity	9.68M	12.38M	20.8M	58.93M	46.44M	39.53M	45.5M
Common Stock	50K	50K	50K	67.97K	67.97K	67.97K	482.4K
Retained Earnings	2.83M	6.18M	13.74M	25.06M	16.32M	10.16M	-10.17M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	3.12M	2.47M	3.33M	4.53M	772.83K	26.27K	1.33M
Minority Interest	0	0	0	0	0	0	0

Cash Flow

	Sep 2018	Sep 2019	Sep 2020	Sep 2021	Sep 2022	Sep 2023	Sep 2024
Cash from Operations+	4.46M	13.2M	6.12M	-2.06M	-1.31M	1.12M	-9.51M
Operating CF Margin %	0.16%	0.4%	0.2%	-0.04%	-0.03%	0.03%	-0.41%
Operating CF Growth %	-	1.96%	-0.54%	-1.34%	0.36%	1.85%	-9.49%
Net Income	7.6M	7.55M	7.56M	11.32M	-7.91M	-6.58M	-8.73M
Depreciation & Amortization	452.73K	418.43K	410.08K	446.88K	533.95K	508.79K	485.73K
Stock-Based Compensation	0	0	0	0	0	0	0
Deferred Taxes	17.54K	-39.63K	-9.89K	-668.34K	-542.38K	1.57M	606.7K
Other Non-Cash Items	-85.19K	112.79K	22.71K	-468.17K	5.97K	-45.74K	186.19K
Working Capital Changes	-3.53M	5.16M	-1.87M	-12.69M	6.6M	5.67M	-2.06M
Change in Receivables	-2.82M	665.49K	-4.11M	-3.87M	-1.55M	4.72M	-1.71M
Change in Inventory	-327.26K	5.59M	888.61K	-451.63K	16.59K	-1.18M	1.64M
Change in Payables	265.17K	-924.44K	639.43K	2.46M	-1.9M	1.64M	143.75K
Cash from Investing+	-145.09K	-86.03K	-51.8K	-27.06M	-3.91M	-44.17K	-361.29K
Capital Expenditures	-145.09K	-86.32K	-51.8K	-13.53M	-93.7K	-44.17K	-245.8K
CapEx % of Revenue	0.01%	0%	0%	0.28%	0%	0%	0.01%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	0	0	0	-26.62M	523	0	-115.49K
Cash from Financing+	-4.91M	-16M	470.14K	26.58M	3.32M	-1.39M	33.95M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-3.06M	-16M	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	0	0	-441.06K	-2.79M	0	0	0
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	4.31M	13.12M	6.06M	-15.59M	-1.41M	1.08M	-9.87M
FCF Margin %	0.15%	0.39%	0.2%	-0.32%	-0.04%	0.03%	-0.43%
FCF Growth %	-	2.04%	-0.54%	-3.57%	0.91%	1.77%	-10.17%
FCF per Share	738.99	2248.83	1039.49	-2956.58	-237.39	181.65	-1624.12
FCF Conversion (FCF/Net Income)	0.59x	1.75x	0.81x	-0.18x	0.15x	-0.18x	1.09x
Interest Paid	183.07K	135.72K	157.53K	149.3K	199.85K	190.18K	304.52K
Taxes Paid	1.7M	2.26M	2.17M	3.27M	2.75M	863.8K	0

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	78.53%	68.45%	45.55%	28.39%	-16.58%	-14.34%	-20.53%
Return on Invested Capital (ROIC)	118.49%	82%	61.22%	29.72%	-10.54%	-6.27%	-18.88%
Gross Margin	47.03%	40.35%	45.9%	52.78%	54.53%	31.93%	26.37%
Net Margin	26.66%	22.73%	24.62%	23.59%	-21.76%	-19.08%	-37.9%
Debt / Equity	0.27x	0.20x	0.13x	0.07x	0.08x	0.14x	0.18x
Interest Coverage	58.55x	75.45x	82.84x	133.76x	-43.22x	-22.49x	-28.83x
FCF Conversion	0.59x	1.75x	0.81x	-0.18x	0.15x	-0.18x	1.09x
Revenue Growth	-	16.54%	-7.6%	56.27%	-16.34%	-19.52%	-28.74%

Frequently Asked Questions

Growth & Financials

Universe Pharmaceuticals Inc. (UPC) reported $46.0M in revenue for fiscal year 2024. This represents a 61% increase from $28.5M in 2018.

Universe Pharmaceuticals Inc. (UPC) saw revenue decline by 28.7% over the past year.

Universe Pharmaceuticals Inc. (UPC) reported a net loss of $17.5M for fiscal year 2024.

Dividend & Returns

Universe Pharmaceuticals Inc. (UPC) has a return on equity (ROE) of -20.5%. Negative ROE indicates the company is unprofitable.

Universe Pharmaceuticals Inc. (UPC) had negative free cash flow of $11.1M in fiscal year 2024, likely due to heavy capital investments.